AWM Investment Company Inc. acquired a new stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,100,473 shares of the company's stock, valued at approximately $4,534,000. AWM Investment Company Inc. owned 1.84% of Eledon Pharmaceuticals at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in ELDN. Tower Research Capital LLC TRC increased its position in shares of Eledon Pharmaceuticals by 418.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,944 shares of the company's stock worth $33,000 after purchasing an additional 6,412 shares in the last quarter. Alpine Global Management LLC acquired a new stake in shares of Eledon Pharmaceuticals during the 4th quarter worth approximately $56,000. ADAR1 Capital Management LLC purchased a new stake in Eledon Pharmaceuticals in the fourth quarter valued at $66,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Eledon Pharmaceuticals in the 4th quarter valued at about $76,000. Finally, Virtu Financial LLC purchased a new stake in shares of Eledon Pharmaceuticals in the 4th quarter valued at approximately $82,000. Institutional investors and hedge funds own 56.77% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on the company. Guggenheim began coverage on Eledon Pharmaceuticals in a research report on Tuesday, January 28th. They issued a "buy" rating and a $9.00 target price for the company. Wall Street Zen upgraded Eledon Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Thursday.
Read Our Latest Stock Report on Eledon Pharmaceuticals
Eledon Pharmaceuticals Stock Performance
NASDAQ ELDN traded up $0.03 during trading on Monday, reaching $3.05. 175,430 shares of the company's stock were exchanged, compared to its average volume of 273,037. The stock has a market cap of $182.64 million, a P/E ratio of -1.52 and a beta of 0.08. Eledon Pharmaceuticals, Inc. has a 1 year low of $2.30 and a 1 year high of $5.54. The company has a 50 day moving average price of $3.12 and a two-hundred day moving average price of $3.88.
Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.20. Research analysts forecast that Eledon Pharmaceuticals, Inc. will post -0.81 EPS for the current fiscal year.
About Eledon Pharmaceuticals
(
Free Report)
Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Featured Articles
Before you consider Eledon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list.
While Eledon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
